CD52 and diffuse large B-cell lymphoma: (96) also presented an observation pertaining to the change of PTCL immunophenotype from CD52+ to CD52- after alemtuzumab treatment, a phenomenon which closely alludes to the documented loss of CD20 expression after rituximab in diffuse large B-cell lymphoma (DLBCL), which is a significant cause of rituximab resistance (97).